-2.26%
Today
Loading 1D prices…
Company profile
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Los Angeles, CA, United States
Employees
29
Fiscal year end
0630
CIK
1527728
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| AZTRAzitra Inc Common Stock | $10.8M | $0.00 | — | -$2.25 | -1.11% | Buy |
| FBLGFibroBiologics Inc. Common Stock | $10.7M | $0.00 | — | -$0.42 | -6.94% | Buy |
| MTVAMetaVia Inc. Common Stock | $10.9M | $0.00 | — | -$7.35 | -5.14% | Buy |
| KALAKALA BIO Inc. Common Stock | $11.1M | $0.00 | — | -$3.31 | +1.60% | Unrated |
| VTGNVistagen Therapeutics Inc. Common Stock | $10.5M | $1.3M | -5491.88% | -$1.83 | 0.00% | Hold |